D-0429-2019 Class III Terminated

Recalled by Lupin Pharmaceuticals Inc. — Baltimore, MD

FDA drug recall D-0429-2019 was initiated by Lupin Pharmaceuticals Inc. on Jan 28, 2019 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: OOS results observed in any other individual impurity and total impurities. The recall status is terminated (terminated Jun 22, 2020). Affected quantity: 9,930 bottles.

Recall details

Product Type
Drugs
Report Date
Feb 13, 2019
Initiation Date
Jan 28, 2019
Termination Date
Jun 22, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
9,930 bottles

Product description

Bimatoprost Ophthalmic Solution 0.03%, packaged in a) 5 mL (NDC 68180-429-02) and b) 7.5 mL (NDC 68180-429-03) bottles, Rx only, Manufactured by: Lupin Limited Pithampur (M.P.) 454 775, INDIA.

Reason for recall

Failed Impurities/Degradation Specifications: OOS results observed in any other individual impurity and total impurities.

Distribution pattern

Nationwide within the United States.

Code information

a) H804506 Exp. 06/2020; 803555 Exp. 04/2020; H805394, Exp. 08/2020 b) H804112 Exp. 05/2020; H803220 Exp. 03/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0429-2019
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0429-2019. Report a data issue: hello@regdatalab.com.